Ugrás a tartalomra
Merck

S0278

Sigma-Aldrich

(±)-Sotalol hydrochloride

≥98% (TLC), powder, β-Adrenoceptor antagonist

Szinonimák:

N-[4-[1-Hydroxy-2-(isopropylamino)ethyl]phenyl]methanesulfonamide hydrochloride

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez


About This Item

Tapasztalati képlet (Hill-képlet):
C12H20N2O3S · HCl
CAS-szám:
Molekulatömeg:
308.82
EC-szám:
MDL-szám:
UNSPSC kód:
12352200
PubChem Substance ID:
NACRES:
NA.77

Terméknév

(±)-Sotalol hydrochloride, ≥98% (TLC), powder

Minőségi szint

Teszt

≥98% (TLC)

Forma

powder

szín

white to off-white

oldhatóság

H2O: 20 mg/mL

kezdeményező

Bayer

SMILES string

Cl.CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1

InChI

1S/C12H20N2O3S.ClH/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17;/h4-7,9,12-15H,8H2,1-3H3;1H

Nemzetközi kémiai azonosító kulcs

VIDRYROWYFWGSY-UHFFFAOYSA-N

Géninformáció

Looking for similar products? Látogasson el ide Útmutató a termékösszehasonlításhoz

Alkalmazás

(±)-Sotalol hydrochloride has been used to test its effect on the cardiac action potential (AP) in human hearts. It has also been used as an β- blocker to determine its effect on free intracellular calcium (Ca2+) release and whole-cell currents in mammalian cancer cells.

Biokémiai/fiziológiai hatások

Potent β-adrenoceptor antagonist; class III antiarrhythmic; prolongs the action potential and increases the refractory period.
Sotalol has a potential to block non-cardioselective β-adrenergic receptors. It acts as an anti-arrhythmic agent and is used as a therapeutic for equine arrhythmias. In addition, sotalol also has an ability to stop atrial fibrillation recurrence.

Tulajdonságok és előnyök

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Tárolási osztály kódja

11 - Combustible Solids

WGK

WGK 3

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable

Egyéni védőeszköz

dust mask type N95 (US), Eyeshields, Gloves


Válasszon a legfrissebb verziók közül:

Analitikai tanúsítványok (COA)

Lot/Batch Number

Nem találja a megfelelő verziót?

Ha egy adott verzióra van szüksége, a tétel- vagy cikkszám alapján rákereshet egy adott tanúsítványra.

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Wei Liu et al.
Pharmaceutical research, 29(7), 1768-1774 (2012-02-22)
To clarify sotalol's classification in the BCS versus BDDCS systems through cellular, rat everted sac and PAMPA permeability studies. Studies were carried out in Madin Darby canine kidney (MDCK) and MDR1-transfected MDCK (MDCK-MDR1) cell lines, rat everted gut sacs and
A Antony Muthu Prabhu et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 96, 95-107 (2012-06-05)
The inclusion complexation behavior of salbutamol, sotalol and atenolol drugs with β-cyclodextrin (β-CD) were investigated by UV-visible, fluorometry, time resolved fluorescence, FT-IR, (1)H NMR, SEM and PM3 methods. The above drugs gave a single emission maximum in water where as
Amee Shah et al.
The American journal of cardiology, 109(11), 1614-1618 (2012-03-27)
Fetal supraventricular tachycardia (SVT) and atrial flutter (AF) can be associated with significant morbidity and mortality. Digoxin is often used as first-line therapy but can be ineffective and is poorly transferred to the fetus in the presence of fetal hydrops.
Mathias Baumert et al.
PloS one, 7(7), e41920-e41920 (2012-08-04)
Increased beat-to-beat variability in the QT interval (QTV) of ECG has been associated with increased risk for sudden cardiac death, but its measurement is technically challenging and currently not standardized. The aim of this study was to investigate the performance
Alexander Burashnikov et al.
Circulation. Arrhythmia and electrophysiology, 5(2), 400-408 (2012-02-11)
Several clinical trials have shown that vernakalant is effective in terminating recent onset atrial fibrillation (AF). The electrophysiological actions of vernakalant are not fully understood. Here we report the results of a blinded study comparing the in vitro canine atrial

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással